Dan Roden
Faculty Member
Last active: 3/24/2020

Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?

Roden DM
Can J Cardiol. 2013 29 (1): 58-66

PMID: 23200096 · PMCID: PMC3529768 · DOI:10.1016/j.cjca.2012.07.845

Responses to drug therapy vary from benefit to no effect to adverse effects which can be serious or occasionally fatal. Increasing evidence supports the idea that genetic variants can play a major role in this spectrum of responses. Well-studied examples in cardiovascular therapeutics include predictors of steady-state warfarin dosage, predictors of reduced efficacy among patients receiving clopidogrel for drug eluting stents, and predictors of some serious adverse drug effects. This review summarizes contemporary approaches to identifying and validating genetic predictors of variability in response to drug treatment. Approaches to incorporating this new knowledge into clinical care, and the barriers to this concept, are addressed.

Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

MeSH Terms (5)

Cardiovascular Agents Cardiovascular Diseases Cardiovascular System Humans Pharmacogenetics

Connections (1)

This publication is referenced by other Labnodes entities: